These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1145 related articles for article (PubMed ID: 10661346)

  • 41. Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer.
    Shu HK; Lee TT; Vigneauly E; Xia P; Pickett B; Phillips TL; Roach M
    Urology; 2001 Jan; 57(1):102-7. PubMed ID: 11164152
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors.
    Wachter S; Gerstner N; Goldner G; Pötzi R; Wambersie A; Pötter R
    Radiother Oncol; 2001 Apr; 59(1):65-70. PubMed ID: 11295208
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
    Zelefsky MJ; Kelly WK; Scher HI; Lee H; Smart T; Metz E; Schwartz L; Fuks Z; Leibel SA
    J Clin Oncol; 2000 May; 18(9):1936-41. PubMed ID: 10784635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.
    Norkus D; Miller A; Kurtinaitis J; Haverkamp U; Popov S; Prott FJ; Valuckas KP
    Strahlenther Onkol; 2009 Nov; 185(11):715-21. PubMed ID: 19899003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.
    Kupelian PA; Reddy CA; Carlson TP; Altsman KA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):904-12. PubMed ID: 12095556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial.
    Wu KL; Jiang GL; Liao Y; Qian H; Wang LJ; Fu XL; Zhao S
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1336-44. PubMed ID: 14630271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
    Aillères N; Azria D; Thézenas S; Barbier N; Fenoglietto P; Delard R; Hay MH; Dubois JB
    Cancer Radiother; 2004 Apr; 8(2):59-69. PubMed ID: 15063872
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.
    Perez CA; Michalski JM; Mansur D; Lockett MA
    Clin Prostate Cancer; 2002 Sep; 1(2):97-104. PubMed ID: 15046700
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Conformal radiotherapy of clinically localized prostate cancer: analysis of rectal and urinary toxicity and correlation with dose-volume parameters.
    Ballare A; Di Salvo M; Loi G; Ferrari G; Beldi D; Krengli M
    Tumori; 2009; 95(2):160-8. PubMed ID: 19579861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques.
    Vranova J; Vinakurau S; Richter J; Starec M; Fiserova A; Rosina J
    Radiat Oncol; 2011 Jul; 6():87. PubMed ID: 21794152
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II dose-escalation study.
    Harsolia A; Vargas C; Yan D; Brabbins D; Lockman D; Liang J; Gustafson G; Vicini F; Martinez A; Kestin LL
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1100-9. PubMed ID: 17967304
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma.
    Zelefsky MJ; Cowen D; Fuks Z; Shike M; Burman C; Jackson A; Venkatramen ES; Leibel SA
    Cancer; 1999 Jun; 85(11):2460-8. PubMed ID: 10357419
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.
    Michalski J; Winter K; Roach M; Markoe A; Sandler HM; Ryu J; Parliament M; Purdy JA; Valicenti RK; Cox JD
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e363-70. PubMed ID: 22633552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prostate and seminal vesicle volume based consideration of prostate cancer patients for treatment with 3D-conformal or intensity-modulated radiation therapy.
    Reddy NM; Nori D; Chang H; Lange CS; Ravi A
    Med Phys; 2010 Jul; 37(7):3791-801. PubMed ID: 20831087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Posttreatment complications of early-stage prostate cancer patients: brachytherapy versus three-dimensional conformal radiation therapy.
    Tsui G; Gillan C; Pond G; Catton C; Crook J
    Cancer J; 2005; 11(2):122-32. PubMed ID: 15969987
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk.
    Fenoglietto P; Laliberte B; Allaw A; Ailleres N; Idri K; Hay MH; Moscardo CL; Gourgou S; Dubois JB; Azria D
    Radiother Oncol; 2008 Jul; 88(1):77-87. PubMed ID: 18215434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use?
    Nitsche M; Brannath W; Brückner M; Wagner D; Kaltenborn A; Temme N; Hermann RM
    Br J Radiol; 2017 Feb; 90(1070):20160370. PubMed ID: 27936891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors.
    Lee CM; Lee RJ; Handrahan DL; Sause WT
    Urology; 2005 Jan; 65(1):114-9. PubMed ID: 15667875
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term urinary toxicity after 3-dimensional conformal radiotherapy for prostate cancer in patients with prior history of transurethral resection.
    Sandhu AS; Zelefsky MJ; Lee HJ; Lombardi D; Fuks Z; Leibel SA
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):643-7. PubMed ID: 11020559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.